Enliven Therapeutics, Inc. · NASDAQ:ELVN

Collins Helen Louise sold 5,000 Enliven Therapeutics, Inc. shares (Form 4)

Traded Sep 17, 2026 · Filed Sep 21, 2026

On Sep 17, 2026, Collins Helen Louise (CHIEF MEDICAL OFFICER) sold 5,000 Enliven Therapeutics, Inc. shares at an average US$50.35 for US$252K under a trading plan, leaving 25,000 shares. Filed Sep 21, 2026 (Form 4).

Sold
5,000 shares
Price
US$50.35 average (US$50.03 to US$51.48)
Value
US$252K
Holding after
25,000 shares
Trading plan
Yes (Made under a plan set in advance)
Role
CHIEF MEDICAL OFFICER

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Sep 17, 2026Common StockOption exercise5,000US$2.4830,000Direct
Sep 17, 2026Common StockSale2,916US$50.0327,084Direct
Sep 17, 2026Common StockSale1,844US$50.7125,240Direct
Sep 17, 2026Common StockSale240US$51.4825,000Direct

Source

View original at SEC

Related